Drug repurposing for Dravet syndrome in scn1Lab−/− mutant zebrafish

Abstract excerpt

Summary Dravet syndrome (DS) is a severe genetic epileptic encephalopathy with onset during the first year of life. Zebrafish models recapitulating human diseases are often used as drug discovery platforms, but also for drug repurposing testing. It was recently shown that pharmacological modulation of three serotonergic (5‐HT) receptors (5‐HT1D, 5‐HT2C, 5‐HT2A) exerts antiseizure effects in a zebrafish scn1Lab−/−...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neonatal and fetal brain pathology
• Share to Neuroscience and Neuropharmacology Research
• Share to Zebrafish Biomedical Research Applications